Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01368562 · ClinicalTrials.gov registry record · NA
Compassionate Use Study of Methylnaltrexone
A NA study of Opioid-induced Constipation, sponsored by Bausch Health Americas.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT01368562 is a NA study of Opioid-induced Constipation that has completed, run by Bausch Health Americas. The registered enrollment target is 26 participants, below the 7,227-participant average among 5 other Opioid-induced Constipation trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01368562, a NA study of Opioid-induced Constipation, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label compassionate use study of subcutaneously administered methylnaltrexone (MNTX) in participants with advance medical illness and opioid-induced constipation.
Conditions Studied
Interventions
- DRUG Methylnaltrexone
Study Locations (1)
New York
- Progenics Pharmaceuticals, Inc. - Tarrytown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2003-01-24 |
| Est. Completion | 2008-06-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01368562
The ClinicalTrials.gov registry entry for NCT01368562 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,227-participant average among 5 other Opioid-induced Constipation trials with a reported enrollment target (100% lower). The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opioid-induced Constipation appearing as the primary indexed condition, and to 1 intervention - of which Methylnaltrexone is the first listed.
NCT01368562 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01368562 about?
NCT01368562 is a clinical study titled "Compassionate Use Study of Methylnaltrexone". This is an open label compassionate use study of subcutaneously administered methylnaltrexone (MNTX) in participants with advance medical illness and opioid-induced constipation.
What is the current status of trial NCT01368562?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2003-01-24. Estimated completion is 2008-06-02.
What conditions does trial NCT01368562 study?
This clinical trial studies the following conditions: Opioid-induced Constipation.
What interventions are being tested in trial NCT01368562?
The interventions under investigation include: Methylnaltrexone (DRUG).
Who is sponsoring clinical trial NCT01368562?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01368562 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid-induced Constipation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
RECRUITING
-
Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation
COMPLETED · Phase 3
-
Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness
COMPLETED · Phase 4
-
A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain
COMPLETED · Phase 3
-
A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.